Abdelrahman Azzam

Abdelrahman Azzam Cardiologist 🫀

في دراسة حديثة تم نشرها في EUROPEAN HEART JOURNAL باشتراك من SCORE2 Writing Group و European Society of Cardiology’s Ca...
08/04/2026

في دراسة حديثة تم نشرها في EUROPEAN HEART JOURNAL باشتراك من SCORE2 Writing Group و European Society of Cardiology’s Cardiovascular Risk Collaboration (CRC) Unit

باسم Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model
باستخدام متغييرات زي الجنس والتدخين وال BMI ووجود مرض السكري من عدمه وتأثيرهم على ال
10-year and 30-year risk of incident HF

Using data from 25 prospective cohorts (14 countries, 611 778 individuals, 21 818 incident HF events)
في الاشخاص ما فوق ال٤٠ عام ولم يسبق لهم الاصابة بأمراض في القلب أو الأوعية الدموية .

2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guidelinefor the Evaluation and Management ofAcute Pulmonary Embolism ...
01/03/2026

2026 AHA/ACC/ACCP/ACEP/CHEST/
SCAI/SHM/SIR/SVM/SVN Guideline
for the Evaluation and Management of
Acute Pulmonary Embolism in Adults.

23/02/2026

Have you read our 2024 , "Guidelines for the Evaluation of Prosthetic Valve Function With Cardiovascular Imaging?" Check it out: https://brnw.ch/21x0a10

It was made in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography!

New RCT in JAMA Cardiology examines the role of Beta blockers after a MI. While these drugs remain a"cornerstone" treatm...
23/02/2026

New RCT in JAMA Cardiology examines the role of Beta blockers after a MI. While these drugs remain a"cornerstone" treatment for patients with reduced heart function
(LVEF

15/08/2025

New ACC guidelines for management of hypertension
Just released today
Link in comments

ليه​ البراسوجريل بيفضل عن البلافيكس مع انه الاكثر انتشارا والاكثر استخداما ده بيرجع لـ٣ عوامل مهمة ▪ rapid onset ...
11/07/2025

ليه​ البراسوجريل بيفضل عن البلافيكس مع انه الاكثر انتشارا والاكثر استخداما
ده بيرجع لـ٣ عوامل مهمة
▪ rapid onset of action
▪ more potent inhibitor of P2Y receptors
▪ its metabolism isn‘t influenced by cytochrome P450

وده اللي تم اثباته ​في دراسة TRITON-TIMI 38
(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet In​hibition with Prasugrel–Thrombolysis in
Myocardial Infarction)
التي قارنت بين عقار بْراسوجريل وعقار كْلوبيدوجريل في مجوعة من ​مرضى
​moderate to severe ACS
​وا​لذين يخضعون لعملية قسطرة قلبية (percutaneous coronary intervention or PCI).
In TRITON-TIMI 38, patients with moderate to high-risk ACS 74% NSTEACS undergoing PCI treated with a P2Y12 inhibitor x 14.5
months:
the primary end point was a composite of death due to cardiovascular causes, nonfatal MI, or nonfatal stroke. Patients who received prasugrel had a significant reduction in the primary end point compared with patients who received clopidogrel (9.9% vs. 12.1%) hazard ratio

Address

Cairo

Telephone

+201060793332

Website

Alerts

Be the first to know and let us send you an email when Abdelrahman Azzam posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Abdelrahman Azzam:

Shortcuts

Share